Heghine Khachatryan: Linking Coagulation, Inflammation, and Neurodegeneration In Neuro-Hemostasis Axis
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared a post on Linkedin:
“The Neuro-Hemostasis Axis: Linking Coagulation, Inflammation, and Neurodegeneration
Emerging evidence is redefining our understanding of neurological disease, highlighting a critical and previously underappreciated interface between hemostasis and brain pathology.
The concept of the ‘neuro-hemostasis axis’ reflects a complex, bidirectional interplay between coagulation pathways, vascular biology, and neuroinflammatory mechanisms — positioning the hemostatic system as an active contributor to neurodegeneration, rather than a passive bystander.
Why This Matters
Accumulating data from translational and clinical studies demonstrate that key components of the hemostatic system exert direct effects on neural tissue:
- Thrombin — beyond coagulation, acts as a potent mediator of neuroinflammation, endothelial activation, and blood–brain barrier disruption
- Fibrin(ogen) — deposition within the central nervous system promotes microglial activation and neurotoxic signaling, accelerating neurodegenerative processes
- Platelets — actively participate in the amyloid cascade, contributing to vascular and neurodegenerative pathology
- Blood–brain barrier dysfunction — facilitates the entry of circulating coagulation factors into the CNS, amplifying inflammation and neuronal injury
A Paradigm Shift
This evolving framework challenges the traditional separation between vascular and neurodegenerative disorders.
Instead, it supports a unifying model in which:
Coagulation, inflammation, and neurodegeneration are mechanistically intertwined
This has profound implications for conditions such as:
- Alzheimer’s disease
- Vascular cognitive impairment
- Neuroinflammatory and paraneoplastic syndromes
Clinical and Research Implications
Understanding the neuro-hemostasis axis opens new avenues for:
- Early identification of at-risk patients
- Biomarker-driven stratification (e.g., fibrinogen, D-dimer, thrombin activity)
- Targeted therapeutic strategies modulating coagulation and inflammation
Take-Home Message
The brain is not isolated from the hemostatic system
it is deeply influenced by it.
Recognizing this connection is essential for advancing both diagnostic precision and therapeutic innovation in neurology and hematology.”
Other posts featuring Heghine Khachatryan on Hemostasis Today.
-
Apr 1, 2026, 17:15Chokri Ben Lamine: Differentiating Reactive from Clonal Causes in Adult Neutrophilia
-
Apr 1, 2026, 16:05Gregory Piazza: Discussing the 2026 AHA/ACC Guidelines for Acute PE at ACC.26
-
Apr 1, 2026, 15:31Simon Senanu: A Stepwise Laboratory Approach for aPTT Prolongation
-
Apr 1, 2026, 15:30Liza Bulsara: Early Clinical Warning Signs of Pediatric Hematologic Disorders
-
Apr 1, 2026, 15:18Gregory Piazza: Proud Moment for Thrombosis Research Group at ACC.26
-
Apr 1, 2026, 15:10Nathan Connel: How Coordinated Advocacy by the WFH Updated the 2025 WHO Essential Medicines List
-
Apr 1, 2026, 14:58Steve Cleveland: Tumor-Educated Platelets as a Platform for Early Cancer Detection
-
Apr 1, 2026, 14:53Angelique Van Ombergen: Joint ESA/NASA Request for Information on Venous Thrombosis in Space
-
Apr 1, 2026, 14:44Chad Mineo: Platelet-Rich Plasma as an Adjunct to Rehabilitation in Grade 2 Hamstring Injuries